Keyphrases
Rozanolixizumab
100%
PVB19
50%
Adaptive Phase
50%
Autoimmune Neuropathy
50%
Sinking Skin Flap Syndrome
50%
Adaptive Platform Trial
50%
CT Halo Sign
50%
Pulmonary Computed Tomography
50%
Angioinvasive Aspergillosis
50%
Halo Sign
50%
Neurolymphomatosis
50%
Myasthenia Gravis
50%
CNM-Au8
50%
Open-label Extension
50%
Zilucoplan
50%
Pridopidine
50%
Neurological System
25%
Treatment-related Adverse Events
22%
Chronic Inflammatory Demyelinating Polyneuropathy
20%
IrAE
16%
Mononeuritis multiplex
16%
Anion Gap Metabolic Acidosis
12%
Choreiform Movement
12%
Acute Chorea
12%
Myeloperoxidase Inhibitor
12%
Once-weekly
11%
Nerve Biopsy
8%
Clinico-radiological Features
8%
International Research Collaboration
8%
Early Cranioplasty
7%
Small Craniotomy
7%
Traumatic Hemorrhage
7%
Parvovirus B19
6%
Erythrovirus
6%
Single-stranded DNA Virus
6%
Erythema Infectiosum
6%
Brachial Plexitis
6%
Parvoviridae
6%
Peroxidase Enzyme
6%
Shared Parameter Model
6%
Probability of Superiority
6%
Revised El Escorial Criteria
6%
Stopping for Futility
6%
Neonatal Fc Receptor
5%
Anaphylactic Reaction
5%
Musk
5%
Myasthenia Gravis Activities of Daily Living
5%
Placebo
5%
Trial Registration
5%
Headache
5%
Medicine and Dentistry
Adverse Event
55%
Chest
50%
Halo Sign
50%
Immune Checkpoint Inhibitor
50%
Neurologic Disease
50%
Mononeuropathy Multiplex
50%
Amyotrophic Lateral Sclerosis
50%
Verdiperstat
50%
Diseases
34%
Immunotherapy
33%
Placebo
27%
Nervous System
25%
Immune-Related Adverse Events
21%
Chronic Inflammatory Demyelinating Polyneuropathy
20%
Organ Systems
16%
Side Effect
16%
Neoplasm
16%
Cancer
16%
Disease Exacerbation
16%
Physical Disease by Body Function
12%
Chorea Minor
12%
Diagnosis
12%
Fifth Disease
10%
Erythroparvovirus
10%
Parvovirus B19
10%
Single-Stranded DNA Virus
10%
Myeloperoxidase Inhibitor
8%
Decompressive Craniectomy
7%
Disease Severity
5%
Slow Vital Capacity
5%
Muscle Weakness
5%
Nicotinamide Adenine Dinucleotide
5%
Adenosine Triphosphate
5%
Nausea
5%
Diarrhea
5%
Assisted Ventilation
5%
Rating Scale
5%
Sensorimotor Neuropathy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Amyotrophic Lateral Sclerosis
100%
Rozanolixizumab
100%
Verdiperstat
50%
Zilucoplan
50%
Myasthenia gravis
50%
Pridopidine
50%
Placebo
33%
Diseases
32%
Adverse Event
27%
Chronic Inflammatory Demyelinating Polyneuropathy
20%
Disease Exacerbation
16%
Cyanocobalamin Deficiency
12%
Chorea Minor
12%
Diarrhea
11%
Human Parvovirus B19
10%
Erythroparvovirus
10%
Erythema Infectiosum
10%
Single-Stranded DNA Virus
10%
Biological Marker
10%
Randomized Clinical Trial
10%
Myeloperoxidase Inhibitor
8%
Muscle Weakness
5%
Subcutaneous Injection
5%
Autoantibody
5%
Headache
5%
Adenosine Triphosphate
5%
Erethism
5%
Protein Tyrosine Kinase
5%
Infection
5%
Immunoglobulin G
5%
Nicotinamide Adenine Dinucleotide
5%
Anaphylaxis
5%
Injection Site Reaction
5%
Nausea
5%
Albumin
5%
Disease Severity
5%
Cholinergic Receptor
5%
Posterior Reversible Encephalopathy Syndrome
5%
Sensorimotor Neuropathy
5%
